Therapeutic area data standards for autosomal dominant polycystic kidney disease: A report from the Polycystic Kidney Disease Outcomes Consortium (PKDOC)

Ronald D. Perrone, Jon Neville, Arlene B. Chapman, Berenice Y. Gitomer, Dana C. Miskulin, Vicente E. Torres, Frank S. Czerwiec, Eslie Dennis, Bron Kisler, Steve Kopko, Holly B. Krasa, Elizabeth Leroy, Juliana Castedo, Robert W. Schrier, Steve Broadbent

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Data standards provide a structure for consistent understanding and exchange of data and enable the integration of data across studies for integrated analysis. There is no data standard applicable to kidney disease. We describe the process for development of the first-ever Clinical Data Interchange Standards Consortium (CDISC) data standard for autosomal dominant polycystic kidney disease (ADPKD) by the Polycystic Kidney Disease Outcomes Consortium (PKDOC). Definition of common data elements and creation of ADPKD-specific data standards from case report forms used in long-term ADPKD registries, an observational cohort (Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease [CRISP] 1 and 2), and a randomized clinical trial (Halt Progression of Polycystic Kidney Disease [HALT-PKD]) are described in detail. This data standard underwent extensive review, including a global public comment period, and is now available online as the first PKD-specific data standard (www.cdisc.org/therapeutic). Submission of clinical trial data that use standard data structures and terminology will be required for new electronic submissions to the US Food and Drug Administration for all disease areas by the end of 2016. This data standard will allow for the mapping and pooling of available data into a common data set in addition to providing a foundation for future studies, data sharing, and long-term registries in ADPKD. This data set will also be used to support the regulatory qualification of total kidney volume as a prognostic biomarker for use in clinical trials. The availability of consensus data standards for ADPKD has the potential to facilitate clinical trial initiation and increase sharing and aggregation of data across observational studies and among completed clinical trials, thereby improving our understanding of disease progression and treatment.

Original languageEnglish (US)
Pages (from-to)583-590
Number of pages8
JournalAmerican Journal of Kidney Diseases
Volume66
Issue number4
DOIs
StatePublished - Oct 1 2015

Keywords

  • Autosomal dominant polycystic kidney disease (ADPKD)
  • Clinical Data Interchange Standards Consortium (CDISC)
  • Polycystic Kidney Disease Outcomes Consortium (PKDOC)
  • consensus data standards
  • controlled terminology
  • data pooling
  • disease progression biomarker
  • standard data structure
  • total kidney volume (TKV)

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Therapeutic area data standards for autosomal dominant polycystic kidney disease: A report from the Polycystic Kidney Disease Outcomes Consortium (PKDOC)'. Together they form a unique fingerprint.

  • Cite this

    Perrone, R. D., Neville, J., Chapman, A. B., Gitomer, B. Y., Miskulin, D. C., Torres, V. E., Czerwiec, F. S., Dennis, E., Kisler, B., Kopko, S., Krasa, H. B., Leroy, E., Castedo, J., Schrier, R. W., & Broadbent, S. (2015). Therapeutic area data standards for autosomal dominant polycystic kidney disease: A report from the Polycystic Kidney Disease Outcomes Consortium (PKDOC). American Journal of Kidney Diseases, 66(4), 583-590. https://doi.org/10.1053/j.ajkd.2015.04.044